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6/j.bAlthough rodent graft-versus-host disease (GVHD) models have suggested that indoleamine 2,3-
dioxygenase (IDO) is a critical regulator of gastrointestinal GVHD, parallel human studies on IDO expression
have not been reported. IDO expression was assessed in 20 patients who underwent duodenal biopsy. IDO
was upregulated in epithelial cells. In situ analyses reveal that macrophages and dendritic cells stain positive
for IDO, but that most of the IDO1 cells were a novel population of CD31CD41IDO1 cells. The proportion
of CD41IDO1T cells was significantly higher in patients with moderate GVHD. In situ regulatory T cell and
Th17 numbers correlated with overall severity. Although needing confirmatory results from larger sample
sets, these data are consistent with the hypothesis that IDO is involved in regulating gastrointestinal GVHD.
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Wider application of allogeneic hematopoietic
stem cell transplantation is restricted because of
graft-versus-host disease (GVHD). The environmen-
tal effects that influence GVHD injury and the natural
regulatory mechanisms by which GVHD is controlled
at the tissue level are incompletely understood [1].
Indoleamine 2,3-dioxygenase (IDO) catalyzes the
first and rate-limiting step of tryptophan catabolism.
Decreased tryptophan and/or increased metabolite
concentrations elicit T cell anergy or apoptosis (re-
viewed in [2]). Several aspects of IDO biology make
it an intriguing target for transplantation and tolerance
(reviewed in [3]).
Previous experimental GVHD models in rodents
by us [4,5] and others [6-8] dissected the role of IDOserm, U728, Paris, France; 2University of Paris
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bmt.2011.08.002in GVHD. We previously reported [4,5] that: (1)
IDO is a critical regulator of GVHD, most strikingly
in the colon; (2) IDO can act at the site of colon
expression to decrease T cell proliferation and
survival, diminishing inflammation and reduce
disease severity; and (3) host IDO expression in both
epithelial cells and antigen-presenting cells affected
GVHD severity. In humans, only 1 in vitro study re-
ported IDO expression by reverse transcription-
polymerase chain reaction of monocytes obtained
from acute GVHD (aGVHD) patients [9].
Herein we report the first study that assayed IDO
protein expression in patients with gastrointestinal
(GI) GVHD.PATIENTS AND METHODS
Patients
Biopsies were performed as diagnostic procedures
for digestive symptoms [10]. The Hospital Saint-Louis
ethical review board approved the design of this study.
A cohort of allografted patients (total n5 20) was stud-
ied after myeloablative conditioning. Their median age
was 34 years. Samples were obtained from: 8 patients (7
males, 1 female; median age 30 years) without patho-
logic GI GVHD (grade 0-1); 5 patients (2 males, 3 fe-
males; median age 47 years) with pathologic GI
GVHD grade 2, and 7 patients (5 males, 2 females;
median age 34 years) with pathologic GI GVHD
grade 3 to 4. All patients underwent biopsy before
being treated with steroids and thus only received cy-
closporine as GVHD prophylaxis. Five nontrans-
planted patients, with active Helicobacter pylori
infection, were used as controls.
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Duodenal biopsies during fiber-optic examination
were performed, as described [10,11]. All biopsies were
performed before any steroid treatment. The
histologic grading of aGVHD was according to Sale
[12] and Epstein [13]. None had evidence of digestive
or systemic viral, bacterial, or fungal infections.
Immunostainings were performed with Ventana
Discovery reagents (Ventana, Phoenix, AZ). For
IDO staining, polyclonal rabbit antibody (gift from
D.M.; dilution 1:500) was used and detected using
a DabMAP kit. Specificity of IDO staining was con-
firmed by incubation of sections with neutralized anti-
body (IDO antibody incubated with blocking peptide
for 2 hours at 4C before incubation with sections).
Double immunofluorescent staining was per-
formed on frozen sections for IDO/CD4, IDO/
CD68, IDO/CD3, IDO/CD123, Foxp3/CD4, and
IL-17/CD4. Regulatory T cell (Treg) and Th17 dou-
ble stainings were performed as described [14]. Addi-
tional staining was performed using anti-CD68
(clone KP-1, DAKO, Carpenteria, CA), anti-CD3
(Biocare, Chicago, IL), and anti-CD123 (clone 6H6,
Biolegend, San Diego, CA) antibodies. Endogenous
peroxidase inhibition and nonspecific binding sites
blocking were systematically performed. Controls
with irrelevant isotypic antibodies, and absence of
primary antibodies were systematically performed.
Antibodieswere covalently linked toAlexafluor 488
or Alexafluor 594 using APEX Antibody Labeling Kits
(Invitrogen, Carlsbad, CA). Sections were incubated in
PBS pH 7.4 containing 5% bovine serum albumin for
30minutes at room temperature.Double immunofluo-
rescent stainings were performed by incubation with
antibodies applied to sections for 1 hour at room tem-
perature. Sections were finally mounted in Vectashield
medium containing 40,6-diamidino-2-phenylindole.
Cell counts and proportions were expressed as median
and interquartile range of the number or proportion of
cells per field at 400magnification.
Samples from patients were identified by anony-
mous 7-digit codes corresponding to laboratory iden-
tification. Biopsies were independently evaluated by
2 examiners (P.R. and A.J.). In all cases of disagreement
between examiners, a common reading was organized
to achieve a consensus on count. For automated counts
of epithelial cells expressing IDO, regions of interest
corresponding to epithelium and excluding infiltrated
cells were independently defined by 2 pathologists
(P.R. and A.J.) using CellSens software (Olympus,
Rungis, France). For each patient, the average number
of epithelial cells expressing IDO was determined on 5
different fields at 400 magnification. Automated
counts of CD41 lymphocytes expressing IDO were
performed usingCellSens software (Olympus) on dou-
ble immunolabeled sections with CD4 and IDO. Foreach patient, the average number of CD41 lympho-
cytes expressing IDO was determined on 5 different
fields at 400 magnification.
Statistical Analyses
Reproducibility of counts was assessed through
examination of discrepancy levels between the exam-
iners and intraclass correlation estimates with 95% con-
fidence intervals. The median level and range of CD4,
CD8, CD68, CD41IDO1, CD681IDO1, Treg, and
Th17 characteristics (cell numbers or their ratios) are
presented. For the comparison on cell count or propor-
tion of Treg, Th17, CD41IDO1, CD681IDO1,
CD41, CD681, IDO1 epithelial cells between the
groups without GVHD (grade 0-1) and mild GVHD
(grade 2), between the groups with mild GVHD and
severe GVHD (grade 3-4), or between the groups of
GVHDandHelicobacter pylori, theMann-Whitney non-
parametric test was used. For the correlation between
CD41IDO1 proportion andTh17 orTreg proportion,
a comparison was performed using Z-test.RESULTS AND DISCUSSION
Figure 1A shows expression of IDO in duodenal
intestinal cells with a morphology and location consis-
tent with epithelial cells, which was up-regulated in
specimens obtained from patients with GVHD com-
pared with those without GVHD. IDO expression in
the epithelial cells of nontransplanted controls with
Helicobacter pylori infection was also detected. These
data are consistent with those in rodents and suggest
that IDO is up-regulated during the GVHD process.
In addition to IDO expression in epithelial cells in
the duodenum of patients with GVHD, IDO-positive
mononuclear cells (MNCs) also were readily detected.
The specificity of the staining was proven by a blocking
peptide (Figure 1A). Double staining surprisingly
revealed that most of these IDO1 MNCs were double-
positive CD41IDO1 cells. Few MNCs were macro-
phages (CD681IDO that were CD42 (Figure 2A)
or CD41 plasmacytoid dendritic cells [DCs]
[CD1231IDO1] (Figure 2B)). Instead, CD41IDO1
coexpressed CD3. Thus, the dominant source of IDO
in MNCs was CD41 T cells (Figure 2B).
We sought to correlate the number of CD41IDO1
Tcells with otherT cell subsets andwith the severity of
GVHD pathologic lesions. As described in Figure 3A
and B, there was no statistical correlation between
CD41IDO1 T cell numbers and Treg cell subsets,
although there was a statistical correlation between
CD4/IL-17 and Treg cells with pathologic grade
of aGVHD, as we have previously described [14].
Moreover, we found a positive correlation (P5 .03) be-
tween the proportion of CD4/IL-17 and CD4/IDO
lymphocytes. The proportion of CD41IDO1 cells
Figure 1. IDO distribution and expression in gut biopsies of transplanted patients without GVHD and with mild and severe GVHD. Control: nontrans-
planted patients infected by Helicobacter pylori. (A) Upper panel: IDO expressing cells were more numerous in patients without GVHD or with grade 2
GVHD than in patients with Grade 3GVHD. Lower panel, specificity control: preincubation of the antibody directed against IDOwith the corresponding
blocking peptide resulted in absence of staining. (B) Double-positive IDO (red)/CD4 (green) cells are absent in biopsies withHelicobacter pylori, present in
transplanted patients without GVHD, and are more numerous in transplanted patients with grade 2 GVHD than with grade 3 GVHD.
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compared with those with grade 0 to 1, albeit lower in
patients with grade 3 to 4 versus grade 2 GVHD
(Figure 3A and B).
Thus, in this first study ever performed in humans,
we report that IDO was up-regulated in epithelial cells
in duodenal biopsy specimens of allogeneic hemato-
poietic stem cell transplantation recipients with
aGVHD at the time of first diagnosis. In situ analyses
revealed that macrophages and DCs stain positive for
IDO, but that most of the IDO1 cells were a novel
population of CD31CD41IDO1 cells. The propor-
tion of CD41IDO1 T cells was significantly higher
in patients with moderate compared with no aGVHD.
In situ Treg andTh17 numbers correlated with overall
severity. However, because numbers of samples ana-
lyzed are small and diverse, we would like to pointout that these observations would need confirmation
with larger sample sets. Furthermore, IDO expression
correlated only with moderate but not severe GVHD;
we do not have a firm conclusion to explain this, and
we could only hypothesize that these regulatory nega-
tive loops are exhausted by unknown mechanisms in
severe forms. Duodenal biopsy was used here, whereas
most experimental data is for IDO in colonic pathol-
ogy. This was based on sample availability in clinical
material that is often limiting.
Consistent with our rodent GVHD data [4] and
experimental data in inflammatory bowel diseases
(reviewed in [15]), we now demonstrate in patients
that aGVHD is associated with IDO up-regulation
in both epithelial cells and antigen-presenting cells
(macrophages, DCs) within GI specimens in the con-
text of aGVHD. Although previous murine models
Figure 2. IDO expression in gut biopsies in macrophages, dendritic, and T cells. (A) Double-positive IDO (red)/CD68 (green) cells are absent in
biopsies with Helicobacter pylori, present in transplanted patients without GVHD, and are more numerous in transplanted patients with histologic
GVHD. (B) Upper panel: double-positive IDO (red)/CD3 (green) cells are more numerous in transplanted patients with histologic grade 2 GVHD
than with grade 3. Lower panel: double-positive IDO (red)/CD123 (green) cells are few in transplanted patients whatever the histologic GVHD grade.
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tions through macrophages or DCs [2], the most pre-
eminent cellular subset in patients with aGVHD in
fact was CD41IDO1 in the cellular infiltrate. Interest-
ingly, in another model of inflammation, acute simian
immunodeficiency infection, a population, that is,
IDO1CD31 T cells have been described in lymphoidtissue [16]. Because the type of mechanistic studies
performed in secondary lymphoid organs and the
GI tract obtained at sequential time points during
GVHD evolution in rodents cannot readily be done
in patients, we can, however, only speculate that the
various IDO positive cell types in humans may be ben-
eficial in preventing GVHD progression.
Figure 3. Counts of inflammatory cells. (A) In control biopsies with Helicobacter pylori, macrophages are prominent and some of them express IDO. In
transplanted patients, T lymphocytes are prominent; among them, CD4 T lymphocytes expressing IDO are predominant in patients with grade 2 GVHD,
whereas Tregs are predominant in patients with grade 3 GVHD. The highest numbers of Th17-positive cells are found in transplanted patients with grade
0 to 1 GVHD. (B) Statistical analysis for CD4/IDO double-positive cells in transplanted patients within the indicated histologic GVHD grade (n 5 20);
Left, no significant correlation between the proportion of CD4/Foxp3 and CD4/IDO lymphocytes; Right, positive correlation (P\.05) between the
proportion of CD4/IL-17 and CD4/IDO lymphocytes. (C) Analysis of CD4 cell subpopulations and epithelial cells expressing IDO after automated
count; the proportion of CD4/Foxp3 cells is significantly higher in grade 2 and grade 3 to 4 GVHD when compared with grade 0 to 1 GVHD. The pro-
portion of CD4/IDO cells is significantly higher in grade 2 GVHDwhen compared with grade 3 to 4 GVHD. A significant decrease was also found for the
proportion of CD4/IL-17 lymphocytes and the histologic grade of GVHD. The number of epithelial cells expressing IDO increases significantly with the
grade of GVHD (ie, grade 0-1 versus grade 2 versus grade 3-4 GVHD). Epithelial cells expressing IDO are significantly numerous in theHelicobacter pylori
group compared with grade 0 to 1 GVHD but significantly lower compared with grade 2 or grade 3 to 4 GVHD.
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tients with the most severe form of aGVHD, there
was a relative paucity of IDO1CD31 T cells. We
speculate that the exceedingly high degree of inflam-
mation may have overwhelmed the IDO system,
which may explain why GVHD is severe in such
patients. Moreover, because IDO alters the balanceof Th17 to Treg in human HIV disease [17], this find-
ing sheds new light on our previous [14], and current,
counterintuitive findings that decreased Th17 and in-
creased Treg actually are associated with more severe
GVHD. In HIV-seropositive subjects, Favre and col-
laborators [17] found that progressive disease is asso-
ciated with the loss of TH17 cells and a reciprocal
Biol Blood Marrow Transplant 18:141-155, 2012 155IDO in Human GVHDincrease in the fraction of the immunosuppressive
Treg cells in rectosigmoid biopsies. The loss of
TH17/Treg balance was associated with induction
of IDO. Thus, Favre et al. [17] postulated that induc-
tion of IDO may represent a critical initiating event
that results in inversion of the TH17/Treg balance
and in the consequent maintenance of a chronic in-
flammatory state in progressive HIV disease. We
thus found similar dysregulation of the Th17/Treg
balance in human GVHD. Decreased IDO produc-
tion in severe GVHD has also been reported in vitro
in humans [9] in stimulated peripheral cells, but to
our knowledge, this study is the first to study human
GVHD in situ.
In conclusion, in humanGVHD IDOmight be in-
volved in controlling early disease. Because IDO up-
regulation and the provision of tryptophan catabolites
can reduce GVHD in rodents [5], these data
strengthen the possibility that such rodent studies
may be translatable into the clinic.ACKNOWLEDGMENTS
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